饮食脂肪摄入量与阿尔茨海默病风险之间的关联:孟德尔的随机化研究
Yunqing Zhu1, Yongbing Lan2, Jun Lv3
1Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China; and Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
The British journal of psychiatry : the journal of mental science
|October 11, 2024
概括
高摄入总食脂肪,特别是和脂肪,增加阿尔茨海默病的风险. 减少和脂肪可能会为这种神经退行性疾病的预防策略提供信息.
科学领域:
- 营养流行病学 营养流行病学
- 神经退行性疾病 神经退行性疾病
- 遗传流行病学遗传流行病学
背景情况:
- 观察性研究表明,饮食脂肪和阿尔茨海默病 (AD) 之间存在联系,但因果关系尚不清楚.
- 调查特定饮食脂肪对阿尔茨海默病风险的因果关系对公众健康至关重要.
研究的目的:
- 确定总脂肪,和脂肪和多不和脂肪 (PUF) 摄入量对患阿尔茨海默病风险的因果关系.
- 为了澄清饮食脂肪对AD风险的独立贡献,控制其他宏观营养素.
主要方法:
- 使用两样本的门德尔随机化 (MR) 方法与来自英国生物银行和FinnGen联盟的全基因组关联研究 (GWAS) 数据.
- 使用多变量MR (MVMR) 来评估脂肪摄入的影响,独立于碳水化合物和蛋白质消费.
- 分析了晚期阿尔茨海默病 (LOAD) 和所有形式的阿尔茨海默病的数据.
主要成果:
- 基因预测较高的总脂肪和和脂肪摄入量与LOAD风险增加有关.
- MVMR分析证实,增加总和和脂肪摄入量显著增加了LOAD和所有形式的阿尔茨海默病的风险.
- 多不和脂肪 (PUF) 摄入量与阿尔茨海默病风险没有显著关联.
结论:
- 总的饮食脂肪,特别是和脂肪,因果关系有助于阿尔茨海默病的风险.
- 这些发现强调了减少和脂肪消费的重要性,作为潜在的预防阿尔茨海默病的预防措施.
- 饮食脂肪对阿尔茨海默症风险的影响似乎独立于其他主要宏观营养素.
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2


